Published in Clin Exp Immunol on December 01, 1990
FK506: the promise and the paradox. Clin Exp Immunol (1991) 0.79
Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production. Clin Exp Immunol (1993) 0.77
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol (1989) 4.30
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
FK-506--how much potential? Immunol Today (1989) 2.20
Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation (1987) 2.15
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation (1987) 1.65
Kidney transplantation in the dog receiving FK-506. Transplant Proc (1987) 1.54
Deliberate donor-specific blood transfusions prior to living related renal transplantation. A new approach. Ann Surg (1980) 1.45
Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. Transplantation (1989) 1.22
Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation (1988) 1.21
Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol (1990) 1.11
The mechanism of action of FK 506. Transplant Proc (1990) 0.99
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology (1986) 0.95
The influence of FK-506 and low-concentration ciclosporin on human lymphocyte activation antigen expression and blastogenesis: a flow cytometric analysis. Scand J Immunol (1990) 0.92
Mediation of antigen-induced suppression of renal allograft rejection by a CD4 (W3/25+) T cell. Transplantation (1989) 0.86
Mediation of the induction of immunologic unresponsiveness following antigen pretreatment by a CD4 (W3/25+) T cell appearing transiently in the splenic compartment and subsequently in the TDL. Transplantation (1989) 0.81
Cyclosporin a can abrogate the sensitizing effect of blood transfusion in rats without interfering with its beneficial influence. Transplantation (1981) 0.78
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
FK 506: an immunosuppressant for the 1990s? Lancet (1991) 2.80
Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol (1999) 2.48
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev (2007) 2.26
FK-506--how much potential? Immunol Today (1989) 2.20
Cyclosporin A inhibits lymphokine production but not the responses of macrophages to lymphokines. Immunology (1983) 1.99
Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat Immunol (2001) 1.95
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway. J Virol (2000) 1.60
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol (1996) 1.53
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood (2001) 1.47
Effects of liver-derived dendritic cell progenitors on Th1- and Th2-like cytokine responses in vitro and in vivo. J Immunol (2000) 1.47
Pregnancy specific beta1-glycoprotein--a product of the syncytiotrophoblast. Experientia (1976) 1.46
Urinary tract infection in old age. Br J Hosp Med (1989) 1.43
Pathological changes developing in the rat during a 3-week course of high dosage cyclosporin A and their reversal following drug withdrawal. Transplantation (1981) 1.38
Toxicity of the immune suppressant cyclosporin A in the rat. J Pathol (1982) 1.38
Immunobiology of cyclosporin A--a review. Aust J Exp Biol Med Sci (1983) 1.31
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Spontaneous and iatrogenically augmented leukocyte chimerism in organ transplant recipients. Transplant Proc (1994) 1.29
Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs. Immunology (1983) 1.27
Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis. Clin Exp Immunol (1994) 1.25
Use of the inhibitory effect of apoptotic cells on dendritic cells for graft survival via T-cell deletion and regulatory T cells. Am J Transplant (2006) 1.24
Fundamental Ca2+ signaling mechanisms in mouse dendritic cells: CRAC is the major Ca2+ entry pathway. J Immunol (2001) 1.23
Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation (1998) 1.22
Cyclosporin: use outside transplantation. BMJ (1991) 1.22
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol (2001) 1.21
Evaluation of carrageenan as an immunosuppressive agent and mediator of intravascular coagulation. Biomedicine (1976) 1.20
Dendritic cells and immune regulation in the liver. Gut (2003) 1.19
Biological and clinical significance of pregnancy-associated alpha2-glycorprotein (alpha/-PAG)-a review. Invest Cell Pathol (1981) 1.18
Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation (1997) 1.17
Delivery of rapamycin to dendritic cells using degradable microparticles. J Control Release (2008) 1.17
Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology (1995) 1.17
Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells. Transplantation (1994) 1.16
Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J Immunol (1997) 1.16
Cyclosporine: immunology, toxicity and pharmacology in experimental animals. Agents Actions (1984) 1.14
New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant (2008) 1.14
Experimental cyclosporin A nephrotoxicity. Br J Exp Pathol (1982) 1.12
Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal. Clin Exp Immunol (1990) 1.11
Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther (2000) 1.10
Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation (1995) 1.10
Cyclosporine-induced fetotoxicity in the rat. Transplantation (1985) 1.10
Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant (2008) 1.10
Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation (2001) 1.09
FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc (1991) 1.09
Toxicity of various carrageenans in the mouse. Br J Exp Pathol (1976) 1.09
Major histocompatibility complex class II antigen (HLA-DR, DQ and DP) expression in human fetal skin. Tissue Antigens (1986) 1.09
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res (2000) 1.08
Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol (2001) 1.08
Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol (1998) 1.07
Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin Exp Immunol (1991) 1.07
Effect of carrageenan on activity of the mononuclear phagocyte system in the mouse. Br J Exp Pathol (1978) 1.07
Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells. J Immunol (2000) 1.07
Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation (1999) 1.05
Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol (1997) 1.05
Serum cyclosporin levels, hepatic drug metabolism and renal tubulotoxicity. Biochem Pharmacol (1984) 1.03
The influence of FK-506 on the thymus: an immunophenotypic and structural analysis. Immunology (1990) 1.03
FK-506 enters the clinic. Immunol Today (1990) 1.03
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res (2001) 1.02
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 1.01
Acute renal failure: factors influencing nephrology referral and outcome. QJM (1997) 1.01
Characterization of the interaction of N-acyl-L-tryptophan benzyl ester neurokinin antagonists with the human neurokinin-1 receptor. J Biol Chem (1994) 1.00
Hospitalization in the first year of renal replacement therapy for end-stage renal disease. QJM (2003) 1.00
Acetone production by methylobacteria. Arch Microbiol (1976) 0.99
Augmentation of delayed-type hypersensitivity to high dose sheep erythrocytes by cyclosporin A in the mouse: influence of drug dosage and route of administration and analysis of spleen cell populations. Clin Exp Immunol (1988) 0.99
Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation (1989) 0.98
Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice. Br J Cancer (1979) 0.98
Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse. Clin Exp Immunol (1983) 0.98
Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation (1998) 0.97
Spleen lymphocyte populations and expression of activation markers in rats treated with the potent new immunosuppressive agent FK-506. Immunology (1988) 0.97
Cyclosporin A prevents suppression of delayed-type hypersensitivity in mice immunized with high-dose sheep erythrocytes. Immunology (1987) 0.97
Neuroendocrine tumours of the gallbladder: three cases and a review of the literature. Postgrad Med J (2009) 0.97
The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation (1993) 0.97
Potentiation of tumour growth by carrageenan. Transplantation (1977) 0.97
Dendritic cells and tolerance induction. Clin Exp Immunol (1996) 0.97
Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation (1996) 0.96
Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance. J Immunol (2001) 0.96
Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. Transplant Proc (1992) 0.96
In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol (1997) 0.96
Nitric oxide production by mouse bone marrow-derived dendritic cells: implications for the regulation of allogeneic T cell responses. Transplantation (1996) 0.96
Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc (1998) 0.95
A toxicological study in rats receiving immunotherapeutic doses of cyclosporin A. Transplantation (1981) 0.95
Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour. Immunology (1986) 0.95
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc (1991) 0.95
Rosette inhibition levels during early human gestation. J Reprod Immunol (1980) 0.94
Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br J Exp Pathol (1983) 0.94
Detection of pregnancy associated alpha 2-glycoprotein (alpha 2-PAG), an immunosuppressive agent, in IgA producing plasma cells and in body secretions. Clin Exp Immunol (1983) 0.94
Effects of the antiprotease Trasylol on peripheral blood leucocytes. Experientia (1978) 0.93
Potential of tolerogenic dendritic cells for transplantation. Semin Immunol (2001) 0.93
Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival. Transplant Proc (1999) 0.93